Paper39475591
Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial.
Ahn DH and 17 others. J Clin Oncol, 2025. Cited by 28 papers, by iCite.
Cite this record
ConductScience Library. Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial. Papers, record 39475591. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39475591
- Disease
- colorectal cancer741 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Colorectal Neoplasms | Major topic |
| Proto-Oncogene Proteins p21(ras) | Major topic |
| Humans | |
| Bevacizumab | |
| Male | |
| Female | |
| Middle Aged | |
| Aged | |
| Adult | |
| Mutation | |
| Leucovorin | |
| Fluorouracil | |
| Camptothecin | |
| Progression-Free Survival | |
| Aged, 80 and over |
Source PubMed
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT03829410 | Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation | Results | Yes | ClinicalTrials.gov |
| NCT06106308 | Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation | Derived from the trial | Yes | ClinicalTrials.gov |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Erratum in | 39561313 | Erratum: Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial. | https://conductscience.org/library/papers/39561313 |
Source PubMed
References39
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34244683 | Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment. | Nat Rev Cancer | 2021 | https://conductscience.org/library/papers/34244683 | PubMed |
| 2 | 27240256 | Data-driven hypothesis weighting increases detection power in genome-scale multiple testing. | Nat Methods | 2016 | https://conductscience.org/library/papers/27240256 | PubMed |
| 3 | 37992175 | HILPS, a long noncoding RNA essential for global oxygen sensing in humans. | Sci Adv | 2023 | https://conductscience.org/library/papers/37992175 | PubMed |
| 4 | 24143206 | The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. | PLoS One | 2013 | https://conductscience.org/library/papers/24143206 | PubMed |
| 5 | 26771021 | The Molecular Signatures Database (MSigDB) hallmark gene set collection. | Cell Syst | 2015 | https://conductscience.org/library/papers/26771021 | PubMed |
| 6 | 32175278 | Resistance Mechanisms to Anti-angiogenic Therapies in Cancer. | Front Oncol | 2020 | https://conductscience.org/library/papers/32175278 | PubMed |
| 7 | 38231047 | Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study. | Clin Cancer Res | 2024 | https://conductscience.org/library/papers/38231047 | PubMed |
| 8 | 35167329 | First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1). | J Clin Oncol | 2022 | https://conductscience.org/library/papers/35167329 | PubMed |
| 9 | 27358379 | Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. | Ann Oncol | 2016 | https://conductscience.org/library/papers/27358379 | PubMed |
| 10 | 37460927 | Novel cancer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance. | J Exp Clin Cancer Res | 2023 | https://conductscience.org/library/papers/37460927 | PubMed |
| 11 | 23828442 | KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials. | Med Oncol | 2013 | https://conductscience.org/library/papers/23828442 | PubMed |
| 12 | 36546659 | Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. | N Engl J Med | 2023 | https://conductscience.org/library/papers/36546659 | PubMed |
| 13 | 34919824 | Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. | Lancet Oncol | 2022 | https://conductscience.org/library/papers/34919824 | PubMed |
| 14 | 15175435 | Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. | N Engl J Med | 2004 | https://conductscience.org/library/papers/15175435 | PubMed |
| 15 | 17442997 | Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. | J Clin Oncol | 2007 | https://conductscience.org/library/papers/17442997 | PubMed |
| 16 | 22319201 | NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. | Mol Cancer Ther | 2012 | https://conductscience.org/library/papers/22319201 | PubMed |
| 17 | 32955176 | KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32955176 | PubMed |
| 18 | 31727675 | Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker Post Hoc Analysis of the VELOUR Trial. | Clin Cancer Res | 2020 | https://conductscience.org/library/papers/31727675 | PubMed |
| 19 | 38587856 | Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer. | Cancer Discov | 2024 | https://conductscience.org/library/papers/38587856 | PubMed |
| 20 | 19224847 | Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19224847 | PubMed |
Cited by25
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42947311 | Targeting G2/M checkpoint vulnerability in homologous recombination-proficient tumors: lessons from ovarian cancer models. | Cell Cycle | 2026 | https://conductscience.org/library/papers/42947311 | PubMed |
| 42907995 | Astragali Radix-Curcumae Rhizoma synergistically potentiates 5-fluorouracil antitumor efficacy in colorectal cancer by disrupting DNA repair-cell cycle coordination. | Chin Med | 2026 | https://conductscience.org/library/papers/42907995 | PubMed |
| 42782861 | KRAS in Colorectal Cancer: Tumorigenesis, Surgical Implications and Evolving Treatment Target. | Curr Oncol | 2026 | https://conductscience.org/library/papers/42782861 | PubMed |
| 42778539 | Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42778539 | PubMed |
| 42510676 | Immune-Metabolic Profiling Reveals Functional Heterogeneity Within Colorectal Cancer Consensus Molecular Subtypes. | Biology (Basel) | 2026 | https://conductscience.org/library/papers/42510676 | PubMed |
| 42443409 | PLK1 inhibition enhances Brentuximab vedotin efficacy in CD30-positive T-cell lymphoma via spindle assembly checkpoint activation. | Leukemia | 2026 | https://conductscience.org/library/papers/42443409 | PubMed |
| 42380087 | α-ketoglutarate accumulation orchestrates immunosuppressive metabolic remodeling to drive cetuximab resistance in metastatic colorectal cancer. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/42380087 | PubMed |
| 42376209 | PLK1: A Promising Therapeutic Target for Prostate Cancer Treatment. | Serican J Med | 2024 | https://conductscience.org/library/papers/42376209 | PubMed |
| 42194957 | Clinical Applications of Liquid Biopsy in Colorectal Cancer: A Focus on Registered Clinical Trials. | Genes (Basel) | 2026 | https://conductscience.org/library/papers/42194957 | PubMed |
| 41782869 | Mass spectrometry-based multi-omics analysis elucidates immune microenvironmental characteristics and the risk of distant metastasis in N1c colorectal cancer. | Front Immunol | 2026 | https://conductscience.org/library/papers/41782869 | PubMed |
| 41523245 | Targeted therapy for KRAS G12C-mutated colorectal cancer: advances, challenges, and future directions. | Am J Cancer Res | 2025 | https://conductscience.org/library/papers/41523245 | PubMed |
| 41458961 | Clinical relevance of PLK1 in epithelial ovarian cancer. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/41458961 | PubMed |
| 41354716 | PLK1 or WEE1 inhibition targets homologous recombination repair proficiency in BRCA1/2 wild-type high-grade serous ovarian cancer. | Cell Death Dis | 2025 | https://conductscience.org/library/papers/41354716 | PubMed |
| 41045302 | PLK1 inhibition enhances gemcitabine-induced apoptosis through PLK1-dependent ERK1/2-Bim and AKT1/Noxa signals in pancreatic cancer cells. | Med Oncol | 2025 | https://conductscience.org/library/papers/41045302 | PubMed |
| 41018484 | Metabolic plasticity drives specific mechanisms of chemotherapy and targeted therapy resistance in metastatic colorectal cancer. | Explor Target Antitumor Ther | 2025 | https://conductscience.org/library/papers/41018484 | PubMed |
| 40935881 | Synthetic lethality in cancer drug discovery: challenges and opportunities. | Nat Rev Drug Discov | 2026 | https://conductscience.org/library/papers/40935881 | PubMed |
| 40615690 | Pan-RAS inhibitors and polo-like kinase 1: promising targets in colorectal cancer. | Oncogene | 2025 | https://conductscience.org/library/papers/40615690 | PubMed |
| 40565172 | Onvansertib-Based Second-Line Therapies in Combination with Gemcitabine and Carboplatin in Patient-Derived Platinum-Resistant Ovarian Carcinomas. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40565172 | PubMed |
| 40496862 | Integrative genomic and single-cell framework identifies druggable targets for colorectal cancer precision therapy. | Front Immunol | 2025 | https://conductscience.org/library/papers/40496862 | PubMed |
| 40412794 | Polo-like kinase 1 inactivation enhances PI3K inhibition-mediated apoptosis of NOTCH1-mutant head and neck squamous cell carcinoma. | Cancer Lett | 2025 | https://conductscience.org/library/papers/40412794 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| KRAS | 3845 | PubTator's text mining | https://conductscience.org/library/genes/3845 | NCBI Gene |
| PLK1 | 5347 | PubTator's text mining | https://conductscience.org/library/genes/5347 | NCBI Gene |
Drugs6
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| BEVACIZUMAB | CHEMBL1201583 | Results | 2 | https://conductscience.org/library/drugs/CHEMBL1201583 | ChEMBL |
| LEUCOVORIN | CHEMBL1679 | Results | 2 | https://conductscience.org/library/drugs/CHEMBL1679 | ChEMBL |
| ONVANSERTIB | CHEMBL1738758 | Results | 2 | https://conductscience.org/library/drugs/CHEMBL1738758 | ChEMBL |
| FLUOROURACIL | CHEMBL185 | Results | 2 | https://conductscience.org/library/drugs/CHEMBL185 | ChEMBL |
| OXALIPLATIN | CHEMBL414804 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL414804 | ChEMBL |
| IRINOTECAN | CHEMBL481 | Results | 2 | https://conductscience.org/library/drugs/CHEMBL481 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39475591
GET https://conductscience.org/api/papers/v1/39475591/references?page=2